Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
AAPS J ; 24(1): 23, 2022 01 06.
Artículo en Inglés | MEDLINE | ID: mdl-34993666

RESUMEN

The recent detection of potent carcinogenic nitrosamine impurities in several human medicines has triggered product recalls and interrupted the supply of critical medications for hundreds of millions of patients, illuminating the need for increased testing of nitrosamines in pharmaceutical products. However, the development of analytical methods for nitrosamine detection is challenging due to high sensitivity requirements, complex matrices, and the large number and variety of samples requiring testing. Herein, we report an analytical method for the analysis of a common nitrosamine, N-nitrosodimethylamine (NDMA), in pharmaceutical products using full evaporation static headspace gas chromatography with nitrogen phosphorous detection (FE-SHSGC-NPD). This method is sensitive, specific, accurate, and precise and has the potential to serve as a universal method for testing all semi-volatile nitrosamines across different drug products. Through elimination of the detrimental headspace-liquid partition, a quantitation limit of 0.25 ppb is achieved for NDMA, a significant improvement upon traditional LC-MS methods. The extraction of nitrosamines directly from solid sample not only simplifies the sample preparation procedure but also enables the method to be used for different products as is or with minor modifications, as demonstrated by the analysis of NDMA in 10+ pharmaceutical products. The in situ nitrosation that is commonly observed in GC methods for nitrosamine analysis was completely inhibited by the addition of a small volume solvent containing pyrogallol, phosphoric acid, and isopropanol. Employing simple procedures and low-cost instrumentation, this method can be implemented in any analytical laboratory for routine nitrosamine analysis, ensuring patient safety and uninterrupted supply of critical medications. Graphical Abstract.


Asunto(s)
Cromatografía de Gases/métodos , Dimetilnitrosamina/análisis , Preparaciones Farmacéuticas/análisis , Cromatografía Liquida/métodos , Contaminación de Medicamentos/prevención & control , Límite de Detección , Espectrometría de Masas/métodos , Nitrosaminas/análisis , Preparaciones Farmacéuticas/química , Reproducibilidad de los Resultados
2.
J Neurochem ; 103(5): 2102-10, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17868298

RESUMEN

In this work, the mechanisms responsible for dopamine (DA) release impairments observed previously in Huntington's disease model R6/2 mice were evaluated. Voltammetrically measured DA release evoked in striatal brain slices from 12-week old R6/2 mice by a single electrical stimulus pulse was only 19% of wild-type (WT) control mice. Iontophoresis experiments suggest that the concentration of released DA is not diluted by a larger striatal extracellular volume arising from brain atrophy, but, rather, that striatal dopaminergic terminals have a decreased capacity for DA release. This decreased capacity was not due to an altered requirement for extracellular Ca(2+), and, as in WT mice, the release in R6/2 mice required functioning vesicular transporters. Catecholamine secretion from individual vesicles was measured during exocytosis from adrenal chromaffin cells harvested from R6/2 and WT mice. While the number of exocytotic events was unchanged, the amounts released per vesicle were significantly diminished in R6/2 mice, indicating that vesicular catecholamines are present in decreased amounts. Treatment of chromaffin cells with 3-nitropropionic acid decreased the vesicular release amount from WT cells by 50%, mimicking the release observed from untreated R6/2 cells. Thus, catecholamine release from tissues isolated from R6/2 mice is diminished because of impaired vesicle loading.


Asunto(s)
Catecolaminas/metabolismo , Exocitosis/fisiología , Enfermedad de Huntington/fisiopatología , Glándulas Suprarrenales/citología , Animales , Encéfalo/metabolismo , Células Cromafines/efectos de los fármacos , Células Cromafines/metabolismo , Convulsivantes/farmacología , Modelos Animales de Enfermedad , Dopamina/metabolismo , Exocitosis/genética , Proteína Huntingtina , Enfermedad de Huntington/patología , Técnicas In Vitro , Iontoforesis/instrumentación , Iontoforesis/métodos , Ratones , Ratones Transgénicos , Proteínas del Tejido Nervioso/genética , Nitrocompuestos/farmacología , Proteínas Nucleares/genética , Propionatos/farmacología
3.
Biophys Chem ; 123(1): 20-4, 2006 Aug 20.
Artículo en Inglés | MEDLINE | ID: mdl-16678962

RESUMEN

The actions of the protonophore CCCP on intracellular Ca2+ regulation and exocytosis in chromaffin cells have been examined. Simultaneous fura-2 imaging and amperometry reveal that exposure to CCCP not only perturbs mitochondrial function but that it also alters vesicular storage of Ca2+ and catecholamines. By disrupting the pH gradient of the secretory vesicle membrane, the protonophore allows both Ca(2+) and catecholamine to leak into the cytosol. Unlike the high cytosolic Ca2+ concentrations resulting from mitochondrial membrane disruption, Ca2+ leakage from secretory vesicles may initiate exocytotic release. In conjunction with previous studies, this work reveals that catalytic and self-sustained vesicular Ca(2+) -induced exocytosis occurs with extended exposure to weak acid or base protonophores.


Asunto(s)
Médula Suprarrenal/metabolismo , Calcio/fisiología , Células Cromafines/metabolismo , Concentración de Iones de Hidrógeno , Médula Suprarrenal/citología , Animales , Calcio/metabolismo , Carbonil Cianuro m-Clorofenil Hidrazona/farmacología , Catecolaminas/metabolismo , Bovinos , Citosol/efectos de los fármacos , Citosol/metabolismo , Exocitosis/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA